# Alkermes plc (ALKS) Stock Analysis: Exploring a 21.82% Potential Upside

- Link: https://www.directorstalkinterviews.com/alkermes-plc-alks-stock-analysis-exploring-a-21-82-potential-upside/4121262448
- Published: 2026-09-14T10:24:52+01:00
- Author: Madison Wilson

Alkermes plc (NASDAQ: ALKS), a prominent player in the specialty and generic drug
manufacturing sector, is drawing significant investor attention with its potential
upside of 21.82%. Headquartered in Dublin, Ireland, Alkermes focuses on addressing
unmet medical needs through its biopharmaceutical innovations. The company’s strong
market presence, with a market capitalization of $7.71 billion, signifies its substantial
influence in the healthcare sector.

Currently trading at $45.97, Alkermes’ stock has experienced a wide 52-week price
range from $26.52 to $55.22, illustrating its volatility and the opportunities for
strategic entry points. Despite a recent price change of -0.14, which maintains 
its price stability, the stock’s future trajectory appears promising, especially
with an average analyst target price of $56.00.

Alkermes is making waves with its robust revenue growth of 27.00%, showcasing its
ability to capture market share and expand its product offerings effectively. However,
the company does not present a trailing P/E ratio, likely due to its strategic reinvestment
into research and development, aimed at sustaining long-term growth.

A notable aspect of Alkermes’ financial outlook is its Forward P/E ratio of 25.14,
indicating investor confidence in its earnings potential. Although traditional valuation
metrics such as PEG ratio and Price/Book are unavailable, the company’s return on
equity stands at a modest 3.85%, reflecting a cautious yet positive return on shareholders’
investments.

Alkermes’ portfolio includes key products like ARISTADA and VIVITROL, targeting 
critical areas such as schizophrenia and opioid dependence. These products, along
with its promising pipeline for neurological disorders, position the company well
to cater to growing therapeutic demands. Additionally, strategic collaboration agreements
with industry giants like Janssen Pharmaceutica enhance its competitive edge and
market penetration.

From a technical standpoint, Alkermes exhibits a Relative Strength Index (RSI) of
77.89, suggesting the stock might be overbought. Investors should be cautious of
potential near-term price corrections. The stock’s 50-day moving average of 49.99
and a 200-day moving average of 38.05 further underline its recent upward momentum.

Analysts have a predominantly positive outlook on Alkermes, with 14 buy ratings,
3 hold ratings, and a lone sell rating. This consensus underscores investor confidence
in Alkermes’ strategic direction and growth potential. The stock’s target price 
range of $38.00 to $72.00 suggests considerable room for upside, particularly for
long-term growth-focused investors.

While Alkermes does not currently offer a dividend yield, its free cash flow of 
$153.38 million empowers the company to reinvest in its product pipeline and strategic
initiatives. The absence of a payout ratio indicates a reinvestment strategy that
prioritizes innovation over immediate shareholder returns.

Investors considering Alkermes should weigh the potential for significant appreciation
against the inherent volatility of the biopharmaceutical sector. As the company 
continues to expand its therapeutic solutions and partnerships, Alkermes remains
a compelling prospect for those seeking to capitalize on the healthcare sector’s
growth trajectory.

Share on:
